Orexigen Drops as Trial Shows Weight Pill Doesn’t Help Heart

Updated on

Shares of Orexigen Therapeutics Inc. tumbled after a safety study of the obesity drug Contrave was halted by researchers who said the pill didn’t show any benefit to the heart, contrary to previous claims.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.